2024 ACR Guideline for the Screening, Treatment, and Management of Lupus Nephritis

Released November 2024, American College of Rheumatology (ACR) Evidence‑rating: Strong recommendation; Conditional recommendation；ISN/RPS‑2018 lupus‑nephritis‑classification adoptedNational C...

Abstract

Objective This 2024 ACR guideline provides updated, actionable‑clinical‑recommendations for screening, biopsy‑indication, induction‑maintenance‑therapy, monitoring, special‑population‑management for lupus‑nephritis (LN) among adult‑SLE‑patients. Major paradigm‑shift: first‑line triple‑immunosuppressive‑induction‑therapy, aggressive‑steroid‑sparing strategy, standardized‑surveillance‑algorithm, and refined‑pregnancy‑and‑CKD‑transition‑pathsAmerican C....

Methods Systematic‑literature‑review; modified‑Delphi‑voting by multi‑disciplinary‑expert‑panel (rheumatology‑nephrology‑patient‑representatives). Two‑tier‑recommendation‑grading: Strong / Conditionalassets.con....

Conclusion All‑SLE‑patients require baseline‑and‑periodic‑LN‑screening. Renal‑biopsy is critical‑for‑diagnosis‑and‑stratification. Active‑proliferative‑LN (class III/IV, ±V) receives triple‑induction‑regimen. Long‑duration‑maintenance‑therapy (3‑5 years) is advised after‑complete‑renal‑response. Hydroxychloroquine and RAAS‑inhibition serve as foundational background‑therapyMedscape.

Keywords: systemic‑lupus‑erythematosus; lupus‑nephritis; glomerulonephritis; screening; induction‑therapy; maintenance‑therapy; biopsy; ACR‑guideline

1. Screening and diagnostic work‑up

1.1 Screening (Strong recommendation)

• For SLE‑patients without known‑LN: screen‑for‑proteinuria every 6‑12 months, or at‑time‑of‑SLE‑extra‑renal‑flareassets.con....
  • New‑onset / recently‑active‑SLE: screen every 6 months.
  • Long‑standing‑stable‑inactive‑SLE: annual‑screening is acceptableassets.con....
• Screening‑assay: spot‑urine‑protein‑to‑creatinine‑ratio (UPCR). UPCR > 0.5 g/g warrants further‑evaluation for‑LNNational C....

1.2 Kidney‑biopsy (Conditional recommendation)

Perform prompt‑percutaneous‑renal‑biopsy (unless contra‑indicated):

1. UPCR > 0.5 g/g without‑alternative‑explanation
2. Unexplained‑decline‑of‑eGFR in‑SLE‑patient
3. Suspected‑LN‑flare; inadequate‑treatment‑response after‑6‑months‑therapyAmerican C...

May‑initiate‑glucocorticoids while‑awaiting‑biopsy‑resultsMedscape.

1.3 Foundational background‑therapy

1. Strong recommendation: hydroxychloroquine for all‑SLE‑patients, including LN‑patients; maintain‑through‑flare‑and‑remissionMedscape.
2. Conditional recommendation: RAAS‑inhibitor (ACE‑I / ARB) for patients with‑proteinuria > 0.5 g/g; monitor‑serum‑creatinine‑and‑potassium after‑initiationMedscape.

2. Induction therapy for active lupus nephritis

Paradigm‑shift: triple‑therapy (glucocorticoids + two‑immunosuppressive‑agents) is now conditional‑recommended‑first‑line‑induction‑instead‑of‑historical‑dual‑regimensAmerican C....

2.1 Active Class III / IV (± V) proliferative LN (Conditional recommendation)

Glucocorticoid backbone:

• IV‑methylprednisolone pulse 250‑1000 mg daily × 1‑3 d;
• Oral‑prednisone starting‑dose ≤ 0.5 mg/kg/day (max 40 mg‑daily), taper‑target: ≤ 5 mg‑prednisone‑daily by 6 months (steroid‑sparing core‑goal)American C....

Choose one triple‑combination:

1. Mycophenolic‑acid‑analog (MPAA) + belimumab (preferred‑with‑prominent‑extra‑renal‑SLE‑manifestations)
2. Mycophenolic‑acid‑analog (MPAA) + calcineurin‑inhibitor‑CNI (preferred‑with‑heavy‑proteinuria ≥ 3 g/g)
3. Low‑dose‑cyclophosphamide (Euro‑Lupus‑regimen) + belimumab (alternative‑option)Medscape

2.2 Pure Class V membranous LN (UPCR > 1 g/g, conditional recommendation)

Triple‑regimen: pulse‑and‑taper‑glucocorticoid + MPAA + CNI (calcineurin‑inhibitor)American C....

2.3 Refractory‑disease

If‑no‑satisfactory‑response‑by‑6‑month‑induction: re‑evaluate‑biopsy‑findings; consider‑rituximab or‑other‑rescue‑strategies within‑multidisciplinary‑settingMedscape.

3. Maintenance‑therapy

• After‑achieving complete‑renal‑response‑CRR: continue‑immunosuppressive‑maintenance‑therapy for total 3‑5 years (conditional‑recommendation)assets.con....
• Preferred‑maintenance‑agents: mycophenolic‑acid‑analog; azathioprine as‑alternative‑(especially‑pregnancy‑planning‑patients).
• Belimumab / CNI may‑be‑continued‑into‑maintenance‑phase‑if‑part‑of‑successful‑induction‑regimenPMC.
• Low‑dose‑glucocorticoid‑tapering‑continues; attempt‑steroid‑discontinuation in‑patients‑with‑sustained‑long‑term‑complete‑renal‑response.

4. Monitoring recommendations

1. Patients not‑yet‑complete‑renal‑response: quantify‑proteinuria, renal‑function, complement‑C3/C4, anti‑dsDNA‑Ab every 3 months (Strong‑recommendation)American C....
2. Patients with‑sustained‑complete‑renal‑response: monitor‑every 3‑6 monthsAmerican C....
3. Clinical‑definition‑complete‑renal‑response (CRR): UPCR < 0.5 g/g, stable‑or‑improved‑eGFR, inactive‑urinary‑sediment.

5. Special‑populations

5.1 Pregnancy‑planning & pregnancy (Conditional‑recommendation, low‑certainty‑evidence)

• Pre‑conception‑goal: achieve‑stable‑renal‑remission ≥ 6‑12 months‑before‑conception.
• Contra‑indicated‑during‑pregnancy: mycophenolate‑mofetil, cyclophosphamide, methotrexate.
• Permitted: hydroxychloroquine; low‑dose‑prednisone; azathioprine (max 2 mg/kg/day); selected‑CNI‑titration‑under‑close‑monitoringBfArM.
• Active‑LN‑during‑pregnancy: multi‑disciplinary‑obstetric‑rheumatology‑nephrology‑joint‑management.

5.2 Children‑adolescents

Apply‑same‑core‑treatment‑principles; dose‑adjust‑by‑body‑surface‑area‑and‑weight; prioritize‑growth‑and‑development‑monitoring.

5.3 Advanced‑CKD / end‑stage‑kidney‑disease

• Continue‑SLE‑disease‑control‑to‑prevent‑extra‑renal‑flare.
• Transplant‑candidates: optimise‑SLE‑systemic‑activity‑prior‑to‑renal‑transplant‑listing.

6. Major updates compared with older ACR LN‑guidance

1. Moved‑from‑dual‑therapy‑toward‑first‑line‑triple‑immunosuppressive‑induction‑regimen.
2. Formal‑steroid‑sparing‑target: prednisone ≤ 5 mg/day‑by‑6‑months‑post‑induction.
3. Standardised‑maintenance‑duration 3‑5 years‑after‑complete‑renal‑response.
4. Clarified‑screening‑frequency‑stratified‑by‑SLE‑disease‑activity.
5. Explicit‑position‑for‑belimumab‑and‑CNI‑within‑first‑line‑induction‑regimens.

Executive‑summary‑slide‑text (PPT‑ready)

2024‑ACR‑Lupus‑Nephritis‑Guideline All‑SLE‑patients require‑periodic‑proteinuria‑screening. Renal‑biopsy‑guides‑therapy‑stratification. Hydroxychloroquine and‑RAAS‑inhibition are‑foundational‑therapy. Active‑class III/IV(±V)‑LN‑receives‑glucocorticoid‑plus‑two‑immunosuppressive‑agents‑as‑triple‑induction‑therapy. Steroid‑sparing‑is‑emphasized. Maintenance‑therapy lasts 3‑5 years‑after‑complete‑renal‑response. Pregnancy‑planning‑needs‑pre‑conception‑remission‑optimization.